Email this article Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers
- Authors: Abrosimov A.Y.1,2, Dvinskikh N.Y.3, Sidorin A.V.3
-
Affiliations:
- Endocrinology Research Center, Ministry of Health of the Russian Federation
- MISIS National Research Technological University
- A. F. Tsyb Medical Radiology Center, Affiliated Department of P. A. Hertzen Federal Medical Research Center, Ministry of Health of the Russian Federation
- Issue: Vol 160, No 5 (2016)
- Pages: 698-701
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/236900
- DOI: https://doi.org/10.1007/s10517-016-3253-1
- ID: 236900
Cite item
Open Access
Access granted
Subscription Access
Abstract
We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign (n=51), malignant (n=87), and borderline (n=53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.
About the authors
A. Yu. Abrosimov
Endocrinology Research Center, Ministry of Health of the Russian Federation; MISIS National Research Technological University
Author for correspondence.
Email: abrosim@mrrc.obninsk.ru
Russian Federation, Moscow; Moscow
N. Yu. Dvinskikh
A. F. Tsyb Medical Radiology Center, Affiliated Department of P. A. Hertzen Federal Medical Research Center, Ministry of Health of the Russian Federation
Email: abrosim@mrrc.obninsk.ru
Russian Federation, Obninsk
A. V. Sidorin
A. F. Tsyb Medical Radiology Center, Affiliated Department of P. A. Hertzen Federal Medical Research Center, Ministry of Health of the Russian Federation
Email: abrosim@mrrc.obninsk.ru
Russian Federation, Obninsk
Supplementary files
